The World Health Organisation (WHO) said on Tuesday that it has approved China's second COVID-19 vaccine 'Sinovac' for emergency use listing.
"WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing," the UN health agency said in a statement.
The vaccine is produced by the Beijing-based pharmaceutical company Sinovac.
"The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe," said Dr Maringela Simao, WHO Assistant-Director General for Access to Health Products.
"We urge manufacturers to participate in the COVAX Facility, share their knowhow and data and contribute to bringing the pandemic under control," Dr. Simo said.
On May 7, WHO granted conditional approval to China's Sinopharm COVID-19 vaccine for emergency use, which helped Beijing to step up its vaccine diplomacy amid the virus surge.
China for its part has approved about five of its vaccines for emergency use and especially using Sinopharm and Sinovac vaccines for both at home and abroad.
China has offered 10 million vaccine doses to COVAX facility which is a WHO backed initiative to provide vaccines to developing countries.
WHO's Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
WHO has already listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Astra Zeneca EU, Janssen, Moderna and Sinopharm vaccines for emergency use.
According to Chinese official media, China has so far administered 600 million doses of vaccines at home so far.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU